Short answer
NOVAVAX INC (NVAX) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Novavax announced third-quarter financial results for the period ended September 30, 2026.
NOVAVAX INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Novavax announced third-quarter financial results for the period ended September 30, 2026
- Full financial results and management commentary are contained in Exhibit 99.1
- Investor focus: vaccine sales, partnership revenue, cash position and profitability trends disclosed in the attached release
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $68.3M, down 3% YoY, while product sales rose 91% to $25.7M as licensing revenue declined
- Net loss narrowed to $31.4M from $202.4M, driven by R&D falling 47% to $52.4M and SG&A declining 25%
- 2026 adjusted revenue framework raised to $385M-$415M, including the $125M Sanofi CIC milestone
- Sanofi partnership adds potential $225M U.S. CIC launch milestone, $75M manufacturing-transfer milestone and high-single-digit to low-teens royalties
- Liquidity declined to $627M from $751M at December 31, 2025, while long-term debt increased to $292.1M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other NOVAVAX INC 8-K filings
Get the next NVAX 8-K as it lands
Follow NVAX for push alerts, or ask the research agent what this filing means.